ArticleGene therapy2013
Effector memory and central memory NY-ESO-1-specific re-directed T cells for treatment of multiple myeloma.
Article in Gene therapy, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 60 citations in OpenAlex.
- Review
- Current Anti-Myeloma Chimeric Antigen Receptor-T Cells: Novel Targets and Methods.Balkan medical journal · 2025Review
- Advances in adoptive cellular immunotherapy and therapeutic breakthroughs in multiple myeloma.Experimental hematology & oncology · 2024Review
- CAR T therapies in multiple myeloma: unleashing the future.Cancer gene therapy · 2024Review
- Joining Forces for Cancer Treatment: From "TCR versus CAR" to "TCR and CAR".International journal of molecular sciences · 2022Review
- Tumor buster - where will the CAR-T cell therapy 'missile' go?Molecular cancer · 2022Review
- Potent, Selective CARs as Potential T-Cell Therapeutics for HPV-positive Cancers.Journal of immunotherapy (Hagerstown, Md. : 1997) · 2021Article
- TCR-like CARs and TCR-CARs targeting neoepitopes: an emerging potential.Cancer gene therapy · 2021Review
- Any closer to successful therapy of multiple myeloma? CAR-T cell is a good reason for optimism.Stem cell research & therapy · 2021Review
- Novel progresses of chimeric antigen receptor (CAR) T cell therapy in multiple myeloma.Stem cell investigation · 2021Review
- Immunotherapy in Hematologic Malignancies: Emerging Therapies and Novel Approaches.International journal of molecular sciences · 2020Review
- Paving the Way toward Successful Multiple Myeloma Treatment: Chimeric Antigen Receptor T-Cell Therapy.Cells · 2020Review
- Unleashing the immune response to NY-ESO-1 cancer testis antigen as a potential target for cancer immunotherapy.Journal of translational medicine · 2020Review
- Identification of two HLA-A*0201 immunogenic epitopes of lactate dehydrogenase C (LDHC): potential novel targets for cancer immunotherapy.Cancer immunology, immunotherapy : CII · 2020Article
- CAR T-Cells in Multiple Myeloma: State of the Art and Future Directions.Frontiers in oncology · 2020Review
- TCR-Like CAR-T Cells Targeting MHC-Bound Minor Histocompatibility Antigens.Frontiers in immunology · 2020Review
- Chimeric antigen receptor T cell therapies for multiple myeloma.Journal of hematology & oncology · 2019Review
- Direct comparison of target-reactivity and cross-reactivity induced by CAR- and BiTE-redirected T cells for the development of antibody-based T-cell therapy.Scientific reports · 2019Article
- Chimeric Antigen Receptor-Modified T Cell Therapy in Multiple Myeloma: Beyond B Cell Maturation Antigen.Frontiers in immunology · 2019Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The cancer-testis antigen NY-ESO-1 is a potential target antigen for immune therapy expressed in a subset of patients with multiple myeloma. We generated chimeric antigen receptors (CARs) recognizing the immunodominant NY-ESO-1 peptide 157-165 in the context of HLA-A*02:01 to re-direct autologous CD8(+) T cells towards NY-ESO-1(+) myeloma cells. These re-directed T cells specifically lysed NY-ESO-1(157-165)/HLA-A*02:01-positive cells and secreted IFNγ. A total of 40% of CCR7(-) re-directed T cells had an effector memory phenotype and 5% a central memory phenotype. Based on CCR7 cell sorting, effector and memory CAR-positive T cells were separated and CCR7(+) memory cells demonstrated after antigen-specific re-stimulation downregulation of CCR7 as sign of differentiation towards effector cells accompanied by an increased secretion of memory signature cytokines such as IL-2. To evaluate NY-ESO-1 as potential target antigen, we screened 78 bone marrow biopsies of multiple myeloma patients where NY-ESO-1 protein was found to be expressed by immunohistochemistry in 9.7% of samples. Adoptively transferred NY-ESO-1-specific re-directed T cells protected mice against challenge with endogenously NY-ESO-1-positive myeloma cells in a xenograft model. In conclusion, re-directed effector- and central memory T cells specifically recognized NY-ESO-1(157-165)/ HLA-A*02:01-positive cells resulting in antigen-specific functionality in vitro and in vivo.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.